glp 1 receptor agonist moa GLP-1 agonists in the treatment of type 2 diabetes – state-of-the-art Frontiers | Mechanisms of action
Description
doi: 10.20945/2359-4292-2023-0123, 12
This is like the unexpected plot twist that can catch us off-guard
For many people in recovery from opioid addiction, the combination of medication, therapy, and peer support through NA meetings make lasting recovery possible
Challenges: The key challenge for Sanofi is competition from more established and better marketed GLP-1 drugs, particularly those from Novo Nordisk and Eli Lilly
L.StanwoodG
